Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07496255

Virtual Reality Cognitive Intervention for Critically Ill Delirium Survivors (VR-Cog)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Indiana University · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to measure the feasibility, acceptability of virtual reality (VR) brain games and estimate their effect on memory, attention, and mood for ICU survivors. The VR program will be used at home through a headset and hand controls.

Detailed description

Acute respiratory failure (ARF) accounts for 2 million admissions to adult intensive care units (ICUs) in the United States annually, and up to 80% of older adults with ARF suffer delirium, a form of ICU-related acute brain dysfunction. Delirium doubles the risk for new cognitive impairment or dementia within 12 months of ICU discharge. In addition, delirium survivors frequently develop related mental health and quality of life impairments. Unfortunately, there are few effective or scalable interventions to improve cognitive outcomes for ICU survivors. Primary Objective Aim 1: Measure the feasibility, acceptability, and adherence of VR-Cog in older adult ICU delirium survivors at risk for ICU-acquired MCI and ADRD. Secondary Objective Aim 2: Estimate the effect of VR-Cog on cognitive performance among older adult ICU delirium survivors. Tertiary/Exploratory/Correlative Objectives Aim 3: Explore the effects of VR-Cog on mental health (depression and anxiety).

Conditions

Interventions

TypeNameDescription
DEVICEVR-based cognitive training programVR-Cog features HomeTown Bound, a suite of 18 modules organized into four training categories: attention, processing speed, memory, and visuospatial.
DEVICEVR-based attention controlVR-AC consists of a library of 9 nature scenes (content provided by Nature Treks VR).

Timeline

Start date
2026-03-19
Primary completion
2027-02-15
Completion
2027-07-15
First posted
2026-03-27
Last updated
2026-04-17

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07496255. Inclusion in this directory is not an endorsement.